Paradigm Biocapital Advisors LP - Q2 2022 holdings

$502 Million is the total value of Paradigm Biocapital Advisors LP's 23 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 87.5% .

 Value Shares↓ Weighting
CCCC SellC4 THERAPEUTICS INC$552,000
-95.4%
73,149
-85.4%
0.11%
-96.6%
FULC ExitFULCRUM THERAPEUTICS INC$0-212,961
-100.0%
-1.33%
KYMR ExitKYMERA THERAPEUTICS INC$0-227,034
-100.0%
-2.54%
PRTA ExitPROTHENA CORP PLC$0-267,946
-100.0%
-2.59%
ZNTL ExitZENTALIS PHARMACEUTICALS INC$0-287,577
-100.0%
-3.51%
HZNP ExitHORIZON THERAPEUTICS PUB L$0-136,243
-100.0%
-3.79%
IOVA ExitIOVANCE BIOTHERAPEUTICS INC$0-907,428
-100.0%
-4.00%
ISEE ExitIVERIC BIO INC$0-910,416
-100.0%
-4.05%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-08-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LEGEND BIOTECH CORP8Q3 202310.7%
MIRATI THERAPEUTICS INC8Q3 202310.9%
VIRIDIAN THERAPEUTICS INC8Q3 20236.8%
IMMUNOCORE HLDGS PLC8Q3 20235.9%
SYNDAX PHARMACEUTICALS INC8Q3 20235.8%
VOR BIOPHARMA INC8Q3 20235.0%
INCYTE CORP7Q3 20238.6%
ARGENX SE7Q3 20238.7%
UNITED THERAPEUTICS CORP DEL7Q3 20237.7%
ALPINE IMMUNE SCIENCES INC7Q3 20232.1%

View Paradigm Biocapital Advisors LP's complete holdings history.

Latest filings
TypeFiled
SC 13G2024-05-02
SC 13G2024-04-08
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Paradigm Biocapital Advisors LP's complete filings history.

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (501529000.0 != 501530000.0)

Export Paradigm Biocapital Advisors LP's holdings